O Ondra Health
Semaglutide Tirzepatide ★
How It Works
BMI Calculator Find your body mass index Weight Loss Estimator Project your progress over time Dose Calculator Understand your dosing schedule
FAQ Blog Get Started Patient Portal
Semaglutide Tirzepatide ★
How It Works
BMI Calculator Weight Loss Estimator Dose Calculator
FAQ Blog
Get Started Patient Portal

ONDRA HEALTH

About Us

Ondra Health was built to make accessing treatment feel clear, straightforward, and grounded in real care — not marketing. It's independently owned and operated, combining clinical experience and operational expertise to create a more thoughtful way to navigate GLP-1 treatment.

Why We Built This

This space has become more complicated than it needs to be.

Between inconsistent pricing, unclear information, and platforms that feel more like subscription products than healthcare, it's often difficult to understand what you're actually signing up for.

From a clinical perspective, we've also seen how important it is for treatment to be individualized — not standardized or rushed.

Ondra was built to simplify both sides of that.

What Makes Ondra Different

Our approach is intentionally simple:

  • Transparent, upfront pricing
  • No unnecessary add-ons or bundled services
  • Provider-led care based on your individual health profile
  • Medications fulfilled through state-licensed compounding pharmacies

We focus on removing friction — not adding to it.

How Care Works

Ondra Health is a platform that connects patients with independent, licensed healthcare providers.

All medical evaluations, prescriptions, and treatment decisions are made by those providers. Medications are fulfilled by regulated compounding pharmacies based on your prescription and location.

Our role is to make that process easier to access, easier to understand, and easier to manage.

Care & Communication

Access is only part of the experience — communication matters just as much.

You should be able to ask questions, understand your options, and feel supported throughout your treatment — not left figuring things out on your own.

We've built Ondra to feel more direct, responsive, and transparent than traditional platforms. As we grow, our focus is to maintain that level of clarity and support across every interaction.

Built to Be Clear

Ondra isn't built around trends, branding, or upsells.

It's built to be something you can rely on — clear information, straightforward access, and honest communication from start to finish.

A Note From Us

Thank you for taking the time to learn about Ondra.

If you choose to move forward with us, our goal is to provide a clear, responsive, and high-quality experience — the kind of care and service we would expect ourselves.

<!-- CMS FIELDS Name: Is Compounded Semaglutide Legal in 2026? The Complete Answer Slug: is-compounded-semaglutide-legal-2026 Category: Getting Started Read Time: 8 min read --> <section class="ondra-article-page"> <div class="ondra-article-hero"> <div class="ondra-article-container"> <div class="ondra-article-meta-row"><span class="ondra-meta-pill">⏱ 8 min read</span><span class="ondra-meta-pill">🏷 Getting Started</span></div> <h1 class="ondra-article-title">Is Compounded Semaglutide Legal in 2026? The Complete Answer</h1> <p class="ondra-article-intro">Yes — with conditions. FDA enforcement discretion for widespread compounding ended April 22, 2025. Compounded semaglutide remains legal through 503A pharmacies in 2026, but the rules have changed significantly. Here is exactly what is allowed, what ended, and what it means for patients.</p> </div> </div> <div class="ondra-article-container ondra-article-body"> <div class="ondra-article-layout" id="ondraArticleLayout"> <div class="ondra-article-main" id="ondraArticleMain"> <a href="/blog" class="ondra-back-link">← Back to all articles</a> <div class="ondra-takeaways-card"> <h2 class="ondra-card-heading">Key takeaways</h2> <div class="ondra-takeaway-item"><span class="ondra-check"><svg width="16" height="16" viewBox="0 0 16 16" fill="none"><circle cx="8" cy="8" r="7" stroke="currentColor" stroke-width="1.4"/><path d="M4.5 8.5L6.5 10.5L11.5 5.5" stroke="currentColor" stroke-width="1.5" stroke-linecap="round" stroke-linejoin="round"/></svg></span><p>Compounded semaglutide is still legal in 2026 through 503A pharmacies under a valid patient-specific prescription with documented individual clinical justification.</p></div><div class="ondra-takeaway-item"><span class="ondra-check"><svg width="16" height="16" viewBox="0 0 16 16" fill="none"><circle cx="8" cy="8" r="7" stroke="currentColor" stroke-width="1.4"/><path d="M4.5 8.5L6.5 10.5L11.5 5.5" stroke="currentColor" stroke-width="1.5" stroke-linecap="round" stroke-linejoin="round"/></svg></span><p>FDA enforcement discretion for widespread compounding ended April 22, 2025, after the semaglutide shortage was declared resolved on February 21, 2025.</p></div><div class="ondra-takeaway-item"><span class="ondra-check"><svg width="16" height="16" viewBox="0 0 16 16" fill="none"><circle cx="8" cy="8" r="7" stroke="currentColor" stroke-width="1.4"/><path d="M4.5 8.5L6.5 10.5L11.5 5.5" stroke="currentColor" stroke-width="1.5" stroke-linecap="round" stroke-linejoin="round"/></svg></span><p>503B outsourcing facilities can no longer legally compound semaglutide. 503A pharmacies remain the legal pathway.</p></div><div class="ondra-takeaway-item"><span class="ondra-check"><svg width="16" height="16" viewBox="0 0 16 16" fill="none"><circle cx="8" cy="8" r="7" stroke="currentColor" stroke-width="1.4"/><path d="M4.5 8.5L6.5 10.5L11.5 5.5" stroke="currentColor" stroke-width="1.5" stroke-linecap="round" stroke-linejoin="round"/></svg></span><p>Cost preference alone is not sufficient justification. Individual clinical need must be documented by the prescribing provider.</p></div><div class="ondra-takeaway-item"><span class="ondra-check"><svg width="16" height="16" viewBox="0 0 16 16" fill="none"><circle cx="8" cy="8" r="7" stroke="currentColor" stroke-width="1.4"/><path d="M4.5 8.5L6.5 10.5L11.5 5.5" stroke="currentColor" stroke-width="1.5" stroke-linecap="round" stroke-linejoin="round"/></svg></span><p>A district court upheld FDA enforcement against 503B compounded semaglutide in April 2025 (<em>OFA v. FDA</em>, N.D. Tex.).</p></div> </div> <div class="ondra-section"><h2>The direct answer</h2><p>Compounded semaglutide is legal in 2026 — but only through 503A compounding pharmacies, under a valid patient-specific prescription, with documented individual clinical justification from a licensed provider. The era of broad enforcement discretion that enabled widespread GLP-1 compounding from 2022 to 2025 is over. What remains is a narrower, more structured legal pathway that legitimate 503A platforms like Ondra Health operate within.</p></div><div class="ondra-section"><h2>The full timeline</h2><div class="ondra-info-card"><p class="ondra-info-title">Key regulatory dates</p><p><strong>March 2022</strong> — FDA adds semaglutide to the drug shortage list. 503A and 503B pharmacies may legally compound at scale.<br/><strong>December 2022</strong> — Tirzepatide added to shortage list.<br/><strong>December 19, 2024</strong> — FDA declares tirzepatide shortage resolved.<br/><strong>February 18, 2025</strong> — 503A enforcement discretion for tirzepatide ends.<br/><strong>February 21, 2025</strong> — FDA declares semaglutide shortage resolved.<br/><strong>March 19, 2025</strong> — 503B enforcement discretion for tirzepatide ends.<br/><strong>April 22, 2025</strong> — 503A enforcement discretion for semaglutide ends.<br/><strong>April 24, 2025</strong> — District court denies injunction in <em>OFA v. FDA</em>, upholding 503B enforcement.<br/><strong>May 22, 2025</strong> — 503B enforcement discretion for semaglutide ends.<br/><strong>2026 (ongoing)</strong> — 503A pharmacies may still legally compound semaglutide and tirzepatide with documented individual clinical justification.</p></div></div><div class="ondra-section"><h2>What 'individual clinical justification' actually means</h2><p>This is the phrase most platforms skip past — and the one patients most need to understand. Under current FDA policy, a 503A pharmacy may legally compound semaglutide for a specific patient when the prescribing provider documents an individual clinical justification beyond cost preference alone.</p><p>Acceptable justifications include a documented allergy or sensitivity to an inactive ingredient in the FDA-approved product, a clinical need for an alternative strength or dosage form not commercially available, or other individualized clinical reasons the provider documents in the patient's record.</p><div class="ondra-info-card"><p class="ondra-info-title">What is not sufficient</p><p>Cost preference alone is explicitly not an acceptable justification under the "essentially a copy" standard in the FD&amp;C Act. A prescription issued solely because compounded semaglutide is cheaper than Wegovy is not compliant with current FDA policy. At Ondra Health, prescriptions are issued solely at the clinical discretion of licensed providers at Wasef Health, PC, who evaluate each patient individually.</p></div></div><div class="ondra-section"><h2>503A vs 503B: which is legal in 2026</h2><div class="ondra-info-card"><p class="ondra-info-title">503A pharmacies — still legal</p><p>State-licensed compounding pharmacies operating under Section 503A of the FD&amp;C Act may still compound semaglutide and tirzepatide for individual patients under valid patient-specific prescriptions with documented clinical justification. All of Ondra Health's pharmacy partners operate under 503A licensure.</p></div><div class="ondra-info-card"><p class="ondra-info-title">503B outsourcing facilities — no longer legal</p><p>FDA-registered 503B outsourcing facilities that produce medications in larger batches without patient-specific prescriptions can no longer legally compound semaglutide or tirzepatide. A district court denied a preliminary injunction against FDA enforcement in April 2025. In April 2026, FDA proposed formally excluding both drugs from the 503B bulks list.</p></div></div><div class="ondra-section"><h2>What to verify when choosing a platform</h2><p>If you are receiving compounded semaglutide through a telehealth platform in 2026, your medication is legal provided the prescription was issued by a licensed provider with documented individual clinical justification through a named 503A pharmacy. The red flags to watch for:</p><p><strong>The pharmacy is not named publicly.</strong> If a platform does not tell you which pharmacy fills your prescription, you cannot verify it is operating under 503A — not 503B or an unregistered source.</p><p><strong>No clinical intake process.</strong> Platforms that ship GLP-1s with minimal or no clinical evaluation are not meeting the "individual clinical justification" standard.</p><p><strong>Suspiciously low pricing with no pharmacy disclosure.</strong> 503B facilities had lower per-unit costs than 503A pharmacies. Platforms pricing far below market rates without pharmacy transparency may be sourcing from non-compliant channels.</p></div> <div class="ondra-section"> <h2>Frequently asked questions</h2> <div class="ondra-faq-item"><h3>Is compounded semaglutide the same as Ozempic or Wegovy?</h3><p>No. Compounded semaglutide contains the same active molecule but is not FDA-approved and is not therapeutically equivalent to Ozempic or Wegovy. The FDA has not reviewed compounded semaglutide for safety, effectiveness, or manufacturing quality. It is prepared by a 503A compounding pharmacy under a patient-specific prescription.</p></div><div class="ondra-faq-item"><h3>Can I still get compounded semaglutide now that the shortage is resolved?</h3><p>Yes — through 503A pharmacies, with a valid patient-specific prescription and documented individual clinical justification. The shortage resolution ended the broad enforcement discretion that allowed 503B facilities to compound it, but 503A compounding with proper clinical justification remains legal.</p></div><div class="ondra-faq-item"><h3>Does Ondra Health comply with current FDA rules?</h3><p>Yes. Ondra works exclusively with 503A pharmacy partners. All prescriptions are issued by licensed providers at Wasef Health, PC with individual clinical evaluation. Ondra does not source medication through 503B outsourcing facilities.</p></div><div class="ondra-faq-item"><h3>What is the 'essentially a copy' rule?</h3><p>The 'essentially a copy' provision in the FD&amp;C Act prohibits compounders from producing medications that are copies of commercially available FDA-approved drugs without individual clinical justification. After the semaglutide shortage resolved, compounding semaglutide solely on the basis of cost is no longer compliant. Individual clinical justification documented by the prescribing provider is required.</p></div> </div> <p class="ondra-disclaimer">† This article is for informational purposes only and does not constitute legal or medical advice. Regulatory information is current as of June 2026. The GLP-1 regulatory environment has been evolving rapidly — verify current FDA guidance directly for the most up-to-date status. Compounded medications are not FDA-approved.</p> </div> <aside class="ondra-article-sidebar" id="ondraSidebarCol"> <div class="ondra-sidebar-track" id="ondraSidebarTrack"> <div class="ondra-sidebar-card-wrap" id="ondraSidebarWrap"> <div class="ondra-sidebar-card" id="ondraSidebarCard"> <div class="ondra-sidebar-top"> <p class="ondra-sidebar-eyebrow">ONDRA HEALTH</p> <h3>Compounded GLP-1 from $149/mo — 503A licensed pharmacies, compliant prescribing</h3> </div> <div class="ondra-sidebar-bottom"> <div class="ondra-sidebar-item"><span><svg width="16" height="16" viewBox="0 0 16 16" fill="none"><circle cx="8" cy="8" r="7" stroke="currentColor" stroke-width="1.4"/><path d="M4.5 8.5L6.5 10.5L11.5 5.5" stroke="currentColor" stroke-width="1.5" stroke-linecap="round" stroke-linejoin="round"/></svg></span><p>All pharmacy partners are 503A licensed</p></div><div class="ondra-sidebar-item"><span><svg width="16" height="16" viewBox="0 0 16 16" fill="none"><circle cx="8" cy="8" r="7" stroke="currentColor" stroke-width="1.4"/><path d="M4.5 8.5L6.5 10.5L11.5 5.5" stroke="currentColor" stroke-width="1.5" stroke-linecap="round" stroke-linejoin="round"/></svg></span><p>Named publicly with license type and state availability</p></div><div class="ondra-sidebar-item"><span><svg width="16" height="16" viewBox="0 0 16 16" fill="none"><circle cx="8" cy="8" r="7" stroke="currentColor" stroke-width="1.4"/><path d="M4.5 8.5L6.5 10.5L11.5 5.5" stroke="currentColor" stroke-width="1.5" stroke-linecap="round" stroke-linejoin="round"/></svg></span><p>Prescriptions issued by Wasef Health, PC providers</p></div><div class="ondra-sidebar-item"><span><svg width="16" height="16" viewBox="0 0 16 16" fill="none"><circle cx="8" cy="8" r="7" stroke="currentColor" stroke-width="1.4"/><path d="M4.5 8.5L6.5 10.5L11.5 5.5" stroke="currentColor" stroke-width="1.5" stroke-linecap="round" stroke-linejoin="round"/></svg></span><p>LegitScript certified · HIPAA compliant</p></div> <a href="https://intake.ondra.health/start-online-visit/glp1" class="ondra-sidebar-button">Start your intake <span aria-hidden="true">→</span></a> <p class="ondra-sidebar-note">Only charged if a provider approves your treatment.</p> </div> </div> </div> </div> </aside> </div> </div> </section>
O
Ondra Health

Personalized GLP-1 treatment plans, guided by licensed providers who care about your journey.

Verify Approval for www.ondra.health

Navigate

Home Patient Portal

Treatments

Semaglutide Tirzepatide Service Areas

Tools

BMI & Weight Loss GLP-1 Eligibility Weight Loss Timeline Calorie Calculator Protein & Water Dose Calculator

Resources

FAQ Blog GLP-1 Reference Pharmacy Partners Contact Us

Legal

Terms of Service Privacy Policy Refund Policy HIPAA Policy Safety Information
Leave Us a Review
Review Us on Trustpilot

© 2026 Ondra Health Inc. All rights reserved.

Ondra Health provides access to telehealth services and compounded medications through licensed providers and pharmacies.